Abstract
Success in new product development is a critical management issue for many firms in high technology industries. No where is this statement more applicable than for firms in the pharmaceutical industry. This industry remains one of the most profitable among U.S. high technology industries. However, the decades of uninterrupted growth have been replaced by a period of dynamic change and instability brought about by spiralling health care expenditures, heightening generic competition, increasing R&D costs, and shortening patent lives.
| Original language | English |
|---|---|
| Title of host publication | Unknown book |
| Publisher | Springer Nature |
| State | Published - 2015 |
